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E. Vannier and P. J. Krause presented an excellent article on “Babesiosis in China, an emerging threat” in the Lancet
Infectious Diseases in December 2014, which updated research on human babesiosis in China. However, a neglected
and emerging issue has not been mentioned in EV & PJK’s article, that is the co-infections with B. microti and P. falciparum
parasites that exist in syndemic areas, spatially in the China-Myanmar border areas of Yunnan province, China. Therefore,
two important issues are addressed in here, including (i) the new emerging infections with Babesia spp. which are
normally ignored in malaria endemic areas due to similarities in pathogenic morphology and clinical symptoms, (ii)
additional consideration on babesiosis rather than drug-resistant malaria when anti-malaria treatment for the febrile
cases in clinics fails.
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E. Vannier and P. J. Krause presented excellent com-
ments on “Babesiosis in China, an emerging threat” [1]
which updated and replenished the review of “human
babesiosis” [2] and reported human babesiosis cases in
China [3–7]. Here, we would like to address a neglected
and emerging issue that babesiosis has sometimes been
misdiagnosed initially as malaria because of the similar-
ities on morphology and symptoms between the two dis-
eases. Especially, the intraerythrocytic ring form stages
of Babesia microti can be misdiagnosed as ring forms of
Plasmodium falciparum which are smaller than that of
P. viviax, for the following three reasons. First, to date,
little was known by medical doctors about the preva-
lence of Babesia spp. in malaria-epidemic areas, where
misidentification as Plasmodium spp. is most prob-
able. For instance, one molecular survey on febrile cases in
malaria epidemic areas of southwestern China has shown
that co-infections with B. microti and P. falciparum para-
sites exist along the China-Myanmar border in Yunnan
province [7]. Secondly, misidentification of babesiosis* Correspondence: ipdzhouxn@sh163.net
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may occur due to some antimalarial drugs, such as
chloroquine and mefloquine, having little effect on
babesiosis [7, 8]. It was also reported that two pa-
tients, with a history of malaria, were tracked follow-
ing treatment with artemether plus pyronaridine in
the China-Myanmar border area [4]. Thirdly, infec-
tions with either Babesia spp. or Plasmodium spp. can
cause severe diseases. The health burden imposed by
both babesiosis and malaria could be substantial in
these syndemic areas of China (Fig. 1), such as Yunnan
province. Artemisinin-resistant P. falciparum malaria
has been reported in Cambodia and the Thailand-
Myanmar border [9]. Based on a small animal model, B.
microti can be responsive to artemisinin derivatives [10].
However, in human babesiosis cases, there are still
insufficient data to confirm that artemisinin derivatives
are also effective to control infections of Babesia.
Therefore, we strongly recommended that infection of
Babesia should be excluded based on the results of
laboratory-based molecular tests when the emergence
of artemisinin-resistant is detected in the syndemic
areas. It will help the standardization of babesiosis
treatment using first choice drugs consisting of atova-
quone and azithromycin and second choice drugs con-
sisting of clindamycin and quinine [2]. Otherwise, theicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Syndemic areas of human babesiosis and falciparum malaria in China (High transmission areas of malaria including Yunnan province and
Hainan province which are the syndemic areas of falciparum and vivax malaria (based on data in 2010). Unstable transmission areas including
Jiangsu, Anhui, Shandong, Henan and Hubei province which are endemic areas of vivax malaria (based on data in 2010). Transmission controlled
areas of malaria, other areas of China and all endemic areas of malaria were classified according to the National malaria control program
((2006-2015); Reported human babesiosis cases and falciparum malaria cases (2010-2014) were demonstrated by histograms)
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doubtedly increase the pressure of artemisinin-resistance
in malaria endemic areas because of the misuse of drugs.
To promote correct identification and effective control
of babesiosis and malaria in syndemic areas, clinical doc-
tors and public health workers should be aware of the
following information: (i) how to apply the molecular
technologies to clearly distinguish babesiosis from mal-
aria in order to overcome the difficulties in microscopy
diagnosis due to their similarities in morphology and
clinical symptoms, and (ii) to consider human babesiosis
rather than drug-resistant malaria when febrile cases in
anti-malaria treatment fail.Competing interests
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